Neuroendocrine prostate cancer (NEPC) is the most aggressive form of prostate cancer, responsible for up to 20% of therapy-resistant cases and associated with rapid disease progression. It is ...

IDEAYA Biosciences', a developmental biotech, valuation declined over 50% since mid-2024. Check out why I'm coming away with ...

Increasing cancer prevalence, including prostate cancer and neuroendocrine tumors ... a chemical that binds to particular markers on cancer cells, are the two main components of radioligand treatments ...

Neuroendocrine cancer is less than 1 percent ... “We’ve heard numerous calls from the ones who've had it. It's helped their cancer markers," said hand surgeon Dr. Eric George who is the ...

According to Precedence Research, the radiopharmaceuticals market size has been estimated at USD 7.51 billion in 2025 and is projected to reach approximately USD 14.44 billion by 2034, growing at a ...

Why ALZpath, GeneDX, 10x Genomics, Protagonist Therapeutics, and Recursion are among the most innovative biotech companies of 2025.

A builder who has been left unable to work following major surgery to remove a tumour says he hasn’t been able to secure any ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...